Sectoral Asset Management Inc. Buys 6,010 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

Sectoral Asset Management Inc. lifted its stake in Roivant Sciences Ltd. (NASDAQ:ROIVFree Report) by 19.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 36,457 shares of the company’s stock after purchasing an additional 6,010 shares during the quarter. Sectoral Asset Management Inc.’s holdings in Roivant Sciences were worth $409,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. FNY Investment Advisers LLC bought a new stake in shares of Roivant Sciences in the 4th quarter worth approximately $33,000. Headlands Technologies LLC bought a new stake in shares of Roivant Sciences in the 4th quarter worth $36,000. Allspring Global Investments Holdings LLC grew its holdings in shares of Roivant Sciences by 42.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 5,385 shares of the company’s stock worth $60,000 after acquiring an additional 1,608 shares during the period. Covestor Ltd grew its holdings in shares of Roivant Sciences by 165,040.0% in the third quarter. Covestor Ltd now owns 8,257 shares of the company’s stock worth $96,000 after acquiring an additional 8,252 shares during the period. Finally, Capstone Investment Advisors LLC bought a new stake in shares of Roivant Sciences in the fourth quarter worth $170,000. 64.76% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ROIV has been the topic of several analyst reports. TheStreet upgraded Roivant Sciences from a “d” rating to a “c+” rating in a research report on Tuesday, February 13th. The Goldman Sachs Group boosted their price objective on Roivant Sciences from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Wolfe Research assumed coverage on Roivant Sciences in a research report on Thursday, February 15th. They issued an “outperform” rating and a $17.00 price objective on the stock. Deutsche Bank Aktiengesellschaft boosted their target price on Roivant Sciences from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Finally, Truist Financial reiterated a “buy” rating and issued a $23.00 target price on shares of Roivant Sciences in a research report on Monday, March 25th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Roivant Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $16.90.

Get Our Latest Stock Analysis on ROIV

Roivant Sciences Trading Down 1.4 %

Shares of ROIV traded down $0.15 during mid-day trading on Friday, reaching $10.47. 4,694,449 shares of the company’s stock traded hands, compared to its average volume of 6,154,324. The stock has a market cap of $8.44 billion, a P/E ratio of 2.07 and a beta of 1.25. The stock’s 50-day moving average is $11.03 and its two-hundred day moving average is $10.75. Roivant Sciences Ltd. has a 12 month low of $8.24 and a 12 month high of $13.24. The company has a debt-to-equity ratio of 0.07, a current ratio of 25.24 and a quick ratio of 25.24.

Roivant Sciences Profile

(Free Report)

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

Featured Articles

Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIVFree Report).

Institutional Ownership by Quarter for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.